
Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type …

Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump. …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

